论文部分内容阅读
目的探讨不同剂量米非司酮治疗子宫肌瘤的效果的疗效与安全性。方法选取我院2010年3月~2016年3月期间收治的120例子宫肌瘤患者,依据随机法划分为参照组与研究组各60例。参照组60例患者给予12.5 mg米非司酮片进行治疗,研究组60例患者给予25 mg米非司酮片进行治疗。对两组患者临床治疗效果及不良反应进行比较。结果研究组治疗有效率显著高于参照组,P<0.05;研究组不良反应发生率显著高于参照组,P>0.05。结论对子宫肌瘤患者给予25 mg米非司酮片进行治疗可取得良好的效果,能够对临床疗效进行提升,但与小剂量组相比其不良反应发生率较高。
Objective To investigate the efficacy and safety of different doses of mifepristone in the treatment of uterine fibroids. Methods A total of 120 patients with uterine fibroids who were treated in our hospital from March 2010 to March 2016 were selected and randomly divided into the reference group and the study group with 60 cases each. Sixty patients in the reference group were treated with 12.5 mg of mifepristone and 60 in the study group were treated with 25 mg of mifepristone. The two groups of patients with clinical effects and adverse reactions were compared. Results The effective rate of treatment in study group was significantly higher than that in reference group (P <0.05). The incidence of adverse reactions in study group was significantly higher than that in reference group (P> 0.05). Conclusion The treatment of uterine fibroids with 25 mg mifepristone tablets can achieve good results, which can improve the clinical efficacy, but the incidence of adverse reactions is higher than that of the low dose group.